Expert consensus on gepant CGRP antagonists for both acute and preventive migraine treatment provides practical clinical guidance for using these oral peptide-pathway drugs.
Key findingExpert consensus on gepant CGRP antagonists for both acute and preventive migraine treatment provide
What the researchers found
Expert consensus on gepant CGRP antagonists for both acute and preventive migraine treatment provides practical clinical guidance for using these oral peptide-pathway drugs.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
No specific numerical outcomes — this is a consensus guideline document.
How the study worked
In publication.
Who was studied
Adults with migraine in Thailand (guideline target population)
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Expert consensus on gepants for acute and preventive treatment of migraine in Thailand.
The journal of headache and pain, 26(1), 131
Citation
Anukoolwittaya, Prakit; Rattanawong, Wanakorn; Vongvaivanich, Kiratikorn; Pongpitakmetha, Thanakit; Thanprasertsuk, Sekh; Poonpedpun, Thaninjitra; Soontrapa, Pannathat; Suwanlaong, Kanokrat; Kongbunkiat, Kannikar; Komonchan, Surasak; Dusitanond, Petcharat; Teekaput, Chutithep; Sirimaharaj, Nopdanai; Yuvasilp, Nadolporn; Tanprawate, Surat. (2025). Expert consensus on gepants for acute and preventive treatment of migraine in Thailand.. The journal of headache and pain, 26(1), 131. https://doi.org/10.1186/s10194-025-02074-4